ADDRESSING UNMET MEDICAL NEEDS
Our most advanced program, neihulizumab, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.
Our most advanced program, neihulizumab, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.
Our Product
INNOVATIVE SOLUTIONS
A growing pipeline of innovative drug candidates for immunemediated diseases.
AltruBio has built a differentiated pipeline of biologic therapies targeting diseases of inflammation with products at various stages of development.
AbGn-168H Neihulizumab
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase II Phase 2a Psoriatic Arthritis trial completed with proof of clinical efficacy achieved.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase II Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of clinical efficacy achieved; continued UC development planned with leiolizumab.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase I Phase 1b multi-dose steroid refractory acute graft versus host disease trial ongoing
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Phase I Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Preclinical Renal Transplantation Non-Human Primate preclinical studies ongoing.
AbGn-268 Leiolizumab
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
MARKET
Preclinical Potency improved version of AbGn-168H for Chronic Inflammatory Disease
Mar, 2020
Neihulizumab
Leiolizumab
Publications
top